Quality of life (QoL) with fulvestrant (FUL)/palbociclib (PAL) versus FUL/placebo (PBO) in postmenopausal women with hormone receptor (HR)+/HER2-endocrine sensitive advanced breast cancer (ABC): Results from GEICAM/2014-12 (FLIPPER) study

Tibau, A.Martinez, M. T.Ramos, M.De la Cruz-Merino, L.Santaballa, A.O'Connor, M.Martinez-Janez, N.Moreno, F.Fernandez-Perez, I.Virizuela, J. A.Alarcon, J.de la Haba-Rodriguez, J.Sanchez-Rovira, P.Albacar, C. R.Bueno, C.Kelly, C.Casas, M.Bezares, S.Rosell, L.Albanell, J.2025-01-072025-01-072021-05-080923-7534https://hdl.handle.net/10668/25703enQuality of life (QoL) with fulvestrant (FUL)/palbociclib (PAL) versus FUL/placebo (PBO) in postmenopausal women with hormone receptor (HR)+/HER2-endocrine sensitive advanced breast cancer (ABC): Results from GEICAM/2014-12 (FLIPPER) studyconference outputopen access10.1016/j.annonc.2021.03.1081569-8041http://www.annalsofoncology.org/article/S0923753421009868/pdf648924400098